Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,159,239
  • Shares Outstanding, K 60,590
  • Annual Sales, $ 103,710 K
  • Annual Income, $ -402,730 K
  • 60-Month Beta 2.22
  • Price/Sales 49.56
  • Price/Cash Flow N/A
  • Price/Book 7.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -1.28
  • Number of Estimates 8
  • High Estimate -0.97
  • Low Estimate -1.50
  • Prior Year -1.96
  • Growth Rate Est. (year over year) +34.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.12 +10.30%
on 07/30/20
90.19 -8.13%
on 07/20/20
-3.40 (-3.94%)
since 07/10/20
3-Month
61.96 +33.73%
on 05/13/20
91.77 -9.71%
on 07/08/20
+15.50 (+23.01%)
since 05/11/20
52-Week
31.99 +159.02%
on 03/17/20
91.77 -9.71%
on 07/08/20
+21.86 (+35.84%)
since 08/09/19

Most Recent Stories

More News
Ultragenyx to Present at Upcoming Investor Conferences

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced...

RARE : 82.86 (-2.69%)
Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates

Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.

BMRN : 116.83 (-1.20%)
EBS : 122.33 (-6.04%)
RARE : 82.86 (-2.69%)
APLT : 27.58 (+2.34%)
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of 47.44% and 53.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

RARE : 82.86 (-2.69%)
Ultragenyx: 2Q Earnings Snapshot

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported second-quarter net income of $25.3 million, after reporting a loss in the same period a year earlier.

RARE : 82.86 (-2.69%)
Ultragenyx Reports Second Quarter 2020 Financial Results and Corporate Update

Two U.S. FDA approvals in second quarter 2020

RARE : 82.86 (-2.69%)
Ultragenyx to Host Conference Call for Second Quarter 2020 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced...

RARE : 82.86 (-2.69%)
Ultragenyx Announces U.S. Commercial Launch of Dojolvi(TM) (triheptanoin), the First FDA-Approved Therapy for the Treatment of Long-chain Fatty Acid Oxidation Disorders

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that Dojolvi(TM)...

RARE : 82.86 (-2.69%)
Ultragenyx Pharm Has Returned 26.5% Since SmarTrend Recommendation (RARE)

SmarTrend identified an Uptrend for Ultragenyx Pharm (NASDAQ:RARE) on May 12th, 2020 at $67.96. In approximately 2 months, Ultragenyx Pharm has returned 26.55% as of today's recent price of $86.00.

RARE : 82.86 (-2.69%)
SmarTrend Watching for Potential Pullback in Shares of Ultragenyx Pharm After 3.75% Gain

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $77.17 to a high of $79.67. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high...

RARE : 82.86 (-2.69%)
SmarTrend Watching for Potential Pullback in Shares of Ultragenyx Pharm After 4.33% Gain

Ultragenyx Pharm (NASDAQ:RARE) traded in a range yesterday that spanned from a low of $70.87 to a high of $76.71. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high...

RARE : 82.86 (-2.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RARE with:

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Key Turning Points

2nd Resistance Point 87.38
1st Resistance Point 85.12
Last Price 82.86
1st Support Level 81.63
2nd Support Level 80.39

See More

52-Week High 91.77
Last Price 82.86
Fibonacci 61.8% 68.93
Fibonacci 50% 61.88
Fibonacci 38.2% 54.83
52-Week Low 31.99

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar